Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetate in postmenopausal women: Effects on lipoproteins, glucose tolerance, endometrial histology, and bleeding

Menopause

Volumn 4, Issue 1, 1997, Pages 10-18

  Gelfand, Morriem ^a   Fugere, Pierre ^b   Bissonnette, François ^b   Wiita, Brinda ^d   Yang, Hwa Ming ^d   Lorrain, Jacques ^c   Ferenczy, Alex ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c Centre Medical Cartierville   (Canada)

^d Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Conjugated estrogens; Dydrogesterone; Estrogen progestin; Hormone replacement therapy; Medroxyprogesterone acetate; Menopause; Progestogens

Indexed keywords

EID: 0007983641     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995;332:1758-66.
2. Judd HL, Cleary RE, Creasman WT, et al. Estrogen replacement therapy. Obstet Gynecol 1981;58:267-75.
3. Whitehead MI, King RJB, McQueen J, Campbell S. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestogen therapy. J R Soc Med 1979;72:322-7.
4. Lane G, Whitehead MI, King RJB. Effects of estrogens and progestogens on the histology, ultrastructure, and biochemistry of the postmenopausal endometrium. Intern Med 1982;2:13-18.
5. Thorn M, Chakravarti S, Oram DH, Studd JWW. Effect of hormone replacement therapy on glucose tolerance in postmenopausal women. Br J Obstet Gynaecol 1977;84:766-84.
6. Spellacy WN, McLeod AGW, Buhi WC, Birk SA. The effects of medroxyprogesterone acetate on carbohydrate metabolism: measurements of glucose, insulin and growth hormone after twelve months' use. Fertil Steril 1972;23:239-44.
7. Turtle S, Turkington V. Effects of medroxyprogesterone acetate on carbohydrate metabolism. Obstet Gynecol 1974;43:605-92.
8. Liew DFM, Ng CSA, Heng SH, Ratnam SS. A comparative study of the metabolic effects of injectable and oral contraceptives. Contraception 1986;33:385-94.
9. Miller VT, Muesing RA, La Rosa JC, et al. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high density lipoprotein subfractions and apolipoprotein A-1. J Obstet Gynecol 1991;77:235-40.
10. Ottoson UB, Johnasson BG, Von Schoulz B. Subfractions of HDL cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. J Obstet Gynaecol 1985;1512:746-50.
11. De Cleyn K, Buytaert P, Coppens M. Carbohydrate metabolism during hormonal substitution therapy. Maturitas 1989;11:235-42.
12. Gaspard UJ, Wery G, Herman P, Scheen AJ, Jamiret CB, Lefebure PJ. Carbohydrate metabolism is not impaired in postmenopausal women using micronised estradiol and dydrogesterone for twelve months. Abstracts of the Xth Meeting of the International Menopause Society, Stockholm, 1993.
13. van der Mooren MJ, Demacker PNM, Thomas CHMG, Borm GF, Rolland R. A 2-year study on the beneficial effects of 17β estradiol dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavorable effects of dydrogesterone. Eur J Obstet Gynaecol Reprod Biol 1993;52:117-23.
14. Siddle NC, Jesinger DR, Whitehead MI, Turner P, Lewis B, Prescott P. Effect on plasma lipids and lipoproteins of postmenopausal estrogen therapy with added dydrogesterone. Br J Obstet Gynaecol 1990;97:1093-100.
15. Crook D, Godsland IF, Hull J, Siddle NC, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17β estradiol: effects on serum lipoproteins and on glucose tolerance. Br J Obstet Gynaecol March 1997.
16. van Amsterdam PH, Overmars H, Scherpenisse PM, de Bree H, Post LC. Dydrogesterone: metabolism in man. Eur J Drug Metab Pharmacokinet 1980;5:173-84.
17. Vermerken AJM, Sultan CH, Goos CMAA. Dydrogesterone has no peripheral (anti)-androgenic properties. In Vivo 1987;1:167-72.
18. Burch DJ, Spowart KJM, Jesinger DK, Randall S, Smith SK. A dose-ranging study of the use of cyclic dydrogesterone with continuous 17β estradiol. Br J Obstet Gynaecol 1995;102:243-8.
19. Martin AJ. Progestins: a review of safety and tolerance in long-term administration. Modern Med 1986;(Suppl)31:12.
20. van der Mooren MJ, Hanselaar AGJM, Borm GF, Rolland R. Changes in the withdrawal bleeding pattern and endometrial histology during 17β-estradiol-dydrogesterone therapy in postmenopausal women: a 2-year prospective study. Maturitas 1995;20:175-80.
21. Woodruff JD, Pickar JH, The Menopause Study Group. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-23.
22. Caudron J, Hendrickx B. Comparison of two equine estrogen-dydrogesterone regimens in the climacteric. Maturitus 1988;10:133-41.
23. Siddle NC, Fraser D, Whitehead MI, et al. Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone. Br J Obstet Gynaecol 1990;97:1101-7.
24. Sherwin BB, Gelfand MM. A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol 1989;73:759-66.
25. Snaith RP, Bridge GWK, Hamilton M. The Leed's scales for the self-assessment of anxiety and depression. Br J Psychiatry 1976;128:156-65.
26. The Writing Group for the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
27. Rees M, Leather A, Pryse-Davies J, Collins SA, Barlow DH, Studd JWW. A first study to compare two dosages of dydrogesterone in opposing the 50 mg estradiol implant. Maturitas 1991;14:9-15.